"What will be the revenue for Taichuan Pharmaceutical this year?"
Lin Ziyi: "After the restructuring of Taichuan Pharmaceutical, this year's revenue should reach two hundred billion, with profits around seventy billion."
Ye Tian: "With seventy billion in profit, even at twenty times the price-to-earnings ratio, that's still one point four trillion."
Lin Ziyi: "But if we go by the fourth quarter, Taichuan Pharmaceutical's revenue for the next year will not be less than three hundred and fifty billion, with profits of one hundred and thirty billion."
Ye Tian: "The profit is not bad. Actually, for such a profitable company, what's the difference whether it's listed or not?"
Lin Ziyi: "Yes. Brother Yang contacted me before, and from his tone, it seems he intends to cash out his shares in Baozhi."
Ye Tian: "Why cash out so early? Does he need money?"
Lin Ziyi: "He has invested in several major projects, on the scale of hundreds of billions."
Ye Tian thought for a moment and said, "Then let's exchange Baozhi's shares for Taichuan Pharmaceutical's shares."
Lin Ziyi: "I have discussed this with Brother Yang, and he is very willing. Moreover, both sides have had the companies appraised, and Taichuan Pharmaceutical's current market value is about seventy percent of Baozhi's. Brother Yang is willing to exchange thirty-five percent of his dry shares for equity in Taichuan Pharmaceutical."
Ye Tian: "That's equivalent to half of Taichuan Pharmaceutical's equity. Hmm, that's acceptable. You can handle this matter yourself."
Lin Ziyi: "By the way, Lingyan's sales are also very good and have entered the right track. Next, I plan to entrust her with the agency for some Wanshou Dan, specifically to sell to wealthy individuals in the United States."
Ye Tian: "You can."
Lin Ziyi: "Also. Lingyan called me yesterday and mentioned some situations."
Ye Tian: "What situations?"
Lin Ziyi: "Lingyan knows some big names in network technology, so she often logs into the dark web. She said that recently, a few people on the dark web have been selling a magical plant, which is said to prolong life but also has very strong side effects."
Ye Tian's heart stirred: "A plant that can prolong life?"
Lin Ziyi nodded: "Lingyan gave me some photos, Brother Tian, take a look."
She opened her phone and flipped through a set of photos for Ye Tian. The photos showed a plant with thick blue-gray leaves and red, snake-like flower spikes, named Red Snake Grass.
Ye Tian looked closely for a few moments and asked, "What are the side effects?"
Lin Ziyi: "It seems to be migraines and mental abnormalities. Some patients with severe side effects have even committed suicide."
Ye Tian: "How much does this plant cost?"
Lin Ziyi: "It was quite expensive initially, one hundred million US dollars per plant. But due to poor sales, the price has dropped repeatedly, and now a whole plant is worth thirty million US dollars."
Ye Tian: "How many plants are on the market?"
Lin Ziyi: "There should be quite a few, at least over a thousand."
Ye Tian: "A thousand plants, thirty billion US dollars. Ziyi, have Han Lingyan buy all the Red Snake Grass for me. I will transfer the money directly to the company account."
Lin Ziyi was surprised: "Brother Tian, buy them all?"
Ye Tian: "Buy them all. Tell her to ship the purchased Red Snake Grass directly to China. I need to verify its effects."
Lin Ziyi: "Okay, I'll tell Lingyan as soon as I get back to the hotel."
Upon returning to the hotel, there were dedicated staff arranging accommodation for the employees. Ye Tian and Lin Ziyi didn't need to worry and went directly to their reserved rooms.
Lin Ziyi took a shower first, and half an hour later, everyone gathered at the hotel restaurant for breakfast.
Only a portion of the company's employees participated in this team-building event; the rest remained at their posts.
Many of these employees were newly recruited, with a significant number coming from Fortune 500 companies, attracted by Baozhi Company's high salaries. Among them were executives and top technical talents.
For instance, over twenty top technical experts were brought in from the world's top three pharmaceutical companies. Their annual salaries each exceeded ten million US dollars, and they could also receive company dividends for research breakthroughs, ranging from millions to over a hundred million US dollars.